Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naive and Relapsed and/or Refractory CLL Patients

被引：7

作者：

Awan, Farrukh T. ^{[1
]}

Pagel, John M. ^{[2
]}

Andritsos, Leslie A.

Gopal, Ajay K. ^{[4
]}

Furman, Richard R. ^{[5
]}

Spurgeon, Stephen ^{[6
]}

Deauna-Limayo, Delva ^{[7
]}

Stromatt, Scott ^{[8
]}

Byrd, John C. ^{[3
]}

机构：

[1] Georgia Hlth Sci Univ, Augusta, GA USA

[2] Fred Hutchinson Canc Res Ctr, Div Oncol, Seattle, WA 98104 USA

[3] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[5] Cornell Univ, Weill Med Coll, New York, NY 10021 USA

[6] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA

[7] Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA

[8] Emergent Prod Dev, Seattle, WA USA

来源：

关键词：

D O I：

10.1182/blood.V118.21.1792.1792

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：782 / 782

页数：1